Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2023
Filter by date:
Showing 1262 press releases before 2023
-
Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
-
Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
-
Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
-
Imfinzi plus chemotherapy granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial
-
AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts
-
First quarter 2022 results
-
Ultomiris approved in the US for adults with generalised myasthenia gravis
-
Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
-
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
-
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
Latest articles and press releases
All of our latest press releases and articles are available to explore
Use a maximum of two downloads here
